Skip to content
Review Open access

Bibliometric analysis of septic cardiomyopathy: Current status, research hotspots, and emerging trends (2015-2025).

Nov 2026 · Medicine · Vol 105 45, pp. e51458 · 0 citations · 55 references
Medicine

Abstract

Background

Septic cardiomyopathy (SCM) represents a life-threatening complication of sepsis. This study provides the first systematic bibliometric analysis and visualization of research in this field during the critical decade following the publication of the "Sepsis-3" definition (2015-2025), highlighting the current status, hotspots, and emerging trends.

Methods

Publications related to SCM were retrieved from the Web of Science Core Collection for the period August 2015 to August 2025. After data cleaning, bibliometric and visualization analyses were conducted using CiteSpace, VOSviewer, Scimago Graphica, and Excel/GraphPad Prism.

Results

The annual number of publications has shown exponential growth since the release of the Sepsis-3 guidelines. China has emerged as the global leader in research output, with Wuhan University identified as the leading institution. The knowledge base is anchored in the Sepsis-3 guidelines and seminal reviews on pathophysiology. Research frontiers have evolved from macro-level concepts such as "inflammation" and "oxidative stress" toward more precise molecular targets, including "ferroptosis," "mitophagy," and the "NLRP3 inflammasome," while "machine learning" has begun to penetrate as an emerging methodological approach.

Conclusion

Over the past decade, research on SCM has shifted from broad pathophysiological concepts toward specific molecular mechanisms. The resulting knowledge map provides a reference for identifying key literature, influential teams, and emerging research directions. Future studies should link mechanistic findings to clinical phenotypes and evaluate diagnostic and therapeutic strategies using patient-centered outcomes.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.